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Somatic mutations of BRAF and NRAS oncogenes are
thought to be among the first steps in melanoma initiation,
but these mutations alone are insufficient to cause tumor
progression. Our group studied the distinct genomic
imbalances of primary melanomas harboring different
BRAF or NRAS genotypes. We also aimed to highlight
regions of change commonly seen together in different
melanoma subgroups. Array comparative genomic
hybridization was performed to assess copy number
changes in 47 primary melanomas. BRAF and NRAS were
screened for mutations by melting curve analysis. Reverse
transcription polymerase chain reaction and fluorescence
in situ hybridization were performed to confirm the array
comparative genomic hybridization results. Pairwise
comparisons revealed distinct genomic profiles between
melanomas harboring different mutations. Primary
melanomas with the BRAF mutation exhibited more
frequent losses on 10q23–q26 and gains on chromosome
7 and 1q23–q25 compared with melanomas with the NRAS
mutation. Loss on the 11q23–q25 sequence was found
mainly in conjunction with the NRAS mutation. Primary
melanomas without the BRAF or the NRAS mutation
showed frequent alterations in chromosomes 17 and 4.
Correlation analysis revealed chromosomal alterations
that coexist more often in these tumor subgroups. To find
classifiers for BRAF mutation, random forest analysis was
used. Fifteen candidates emerged with 87% prediction
accuracy. Signaling interactions between the EGF/
MAPK–JAK pathways were observed to be extensively
altered in melanomas with the BRAF mutation. We found
marked differences in the genetic pattern of the BRAF
and NRAS mutated melanoma subgroups that might
suggest that these mutations contribute to malignant
melanoma in conjunction with distinct cooperating
oncogenic events. Melanoma Res 00:000–000 c 2012
Wolters Kluwer Health | Lippincott Williams & Wilkins.
Melanoma Research 2012, 00:000–000
Keywords: array comparative genomic hybridization, BRAF mutation, NRAS
mutation, primary melanoma, signaling pathway
aDepartment of Preventive Medicine, Faculty of Public Health, bDepartment
of Dermatology, Faculty of Medicine, Medical and Health Science Center,
cPublic Health Research Group of the Hungarian Academy of Sciences,
University of Debrecen, Debrecen, Hungary and dEvolutionary Systems Biology
Group, Institute of Biochemistry, Biological Research Centre, Szeged, Hungary
Correspondence to Margit Bala´zs, PhD, DSc, Division of Biomarker Analysis,
Department of Preventive Medicine, Faculty of Public Health, Medical
and Health Science Center, University of Debrecen, Kassai str. 26,
H-4028 Debrecen, Hungary
Tel:/fax: + 36 524 172 67;
e-mail: balazs.margit@sph.unideb.hu
Received 11 October 2011 Accepted 22 February 2012
Introduction
Skin cancer is the most widespread malignancy in most
countries and although melanoma represents only a small
subset, it is one of the most dangerous cutaneous neo-
plasms that arise from pigmented cells. As soon as the
first distant metastasis appears, the disease becomes one
of the most aggressive and chemoresistant tumors. Even
though the early recognition of cutaneous melanoma has
improved, the mortality rate has not changed and has
shown stabilization in Australia, USA, and Europe [1–3].
Thus, it is becoming a major public health problem,
which requires efforts to determine the genetic and envi-
ronmental factors of melanoma genesis and progression [4].
Different subtypes of the disease represent diverse en-
tities, as there are marked differences in their biological
behavior, and it is suggested that this morphologic hetero-
geneity originates from underlying genetics, leading to
diverse pathways of tumor development and progression [5].
For example, activation of the mitogen-activated protein
kinase (EGF/MAPK) pathway through mutations in BRAF
or NRAS and loss of PTEN is a compulsory event in the
subgroup of melanoma that develop in skin that was ex-
posed to intermittent UV radiation [6].
Until recently, histopathology has been the main standard
for the diagnosis of melanoma, but there are already some
reports showing that genetic data provided by compara-
tive genomic hybridization (CGH) can yield helpful diag-
nostic information in cases that are ambiguous on the
basis of histopathologic assessment [7]. The recent devel-
opment of high-resolution molecular biological techniques
has advanced our ability to detect genetic alterations in
the entire genome. The largest outcome study combined
the results of mutational analysis of BRAF and NRAS
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oncogenes with array CGH (aCGH) data in 126 melano-
mas from individuals with varying UV exposure and has
yielded interesting information: several marked differ-
ences in aberrant genomic regions and in the frequencies
of BRAF and NRAS mutations were found in the groups
in which the degree of sun exposure differed [5]. These
findings indicated distinct genetic pathways in the devel-
opment of melanoma that could affect the design of
targeted therapeutic interventions in the future. The
study also revealed that melanoma is a heterogenous
disease with an unpredictable clinical course. Using tiling-
resolution bacterial artificial chromosome (BAC) aCGH,
another study observed discrete copy number alterations
associated with mutations in various melanoma genes,
including BRAF, NRAS, PTEN, and TP53, in 47 different
melanoma cell lines. Moreover, two recent landmark
studies investigated the distinct genome-wide alterations
in DNA copy number associated with BRAF or NRAS
mutation status in 43 primary human melanomas and
several melanoma cell lines [8–10]. In addition, we re-
cently found that coamplification of candidate oncogenes
in the 11q13 region with either the BRAF or the NRAS
mutation might be more important for prognosis than
these alterations alone [11]. These previous reports sug-
gested that even though both BRAFand NRAS function as
key molecules along the EGF/MAPK pathway, they may
cooperate with different oncogenic events during mela-
noma development.
In this study, aCGH was used to assess gene copy number
changes in 47 primary cutaneous melanomas. Thereafter,
these lesions were screened for the most common BRAF
and NRAS mutations found in melanoma to establish
distinct mutation subgroups of the disease such as BRAF
mutated or NRAS mutated or wild-type (WT) (assigned
as BRAFmut, BRAFWT and NRASmut, NRASWT, respec-
tively) for both of these oncogenes. It is well known that
activating mutations in BRAF and NRAS are, so far, the
most common single mutations detected in melanoma
and the majority of benign nevi, but it is also clear that
isolated mutations are not sufficient to initiate human
melanoma in vivo. As the significance of BRAF and NRAS
mutations in melanoma has remained unclear, the two
major objectives of our investigation were: (a) to eluci-
date chromosomal regions that differ in copy number
between these genetically different melanomas and (b)
to examine the correlations between these regions (which
covers important onco-suppressor and/or tumor-suppres-
sor genes) to explore whether some of them act together
in generating group differences. Another major focus of
our study was to explore a possible set of gene copy
number alterations that have significant impacts on
dysregulation of the EGF/MAPK pathway along with
the BRAF mutation. Furthermore, we obtained the entire
set of a signaling pathway data cataloged in a novel data-
base and estimated the copy number changes of each of
these pathway genes using the closest BAC clone to
investigate the large-scale modifications in signaling in-
teractions (later referred as cross-talks) between and
within different pathways in a series of primary melanomas.
Materials and methods
Tumor samples and DNA isolation
Tissue samples were obtained from 47 patients who were
diagnosed with primary cutaneous melanoma and subse-
quently underwent surgery between 1995 and 2006 at the
University of Debrecen, Medical and Health Science
Center, Department of Dermatology, Hungary. The study
was approved by the Regional and Institutional Ethics
Committee, Medical and Health Science Center, Uni-
versity of Debrecen, and was conducted according to
regulations. Tumor diagnosis was made on the basis of
formalin-fixed paraffin embedded tissue sections using
hematoxylin and eosin staining. A primary melanoma
tissue that was used to extract DNA for aCGH was con-
sidered suitable for study if the proportion of tumor cells
was higher than 70%. Melanoma tumor staging was deter-
mined according to the current tumor node metastasis
staging system [12].
The follow-up period was 4 years. Table 1 summarizes the
clinicopathological data. Genomic DNA was obtained
from frozen tissue samples using the DNeasy kit (Quiagen,
Hilden, Germany) and the G-spin Genomic DNA Extrac-
tion Kit (Macherey-Nagel, Du¨ren, Germany) according to
the manufacturers’ instructions.
Array comparative genomic hybridization experiments
aCGH experiments were conducted on HumArray 3.1
obtained from the University of California, San Francisco
Cancer Center Array Core, as described before [13]. This
array contains 2464 BAC and P1 clones, printed in tri-
plicate and covering the genome at roughly 1.4Mb reso-
lution. Hybridization and imaging setup were performed
as previously described [14]. The acquired microarray
images were analyzed by Spot and Sproc software (UCSF
Comprehensive Cancer Center, University of California,
San Fransico, California, USA) [15]. DNA spots were
automatically segmented, local background was sub-
tracted, and the intensity ratio of the two dyes for each
spot was calculated by log2-transformed modeling. Spots
for which the log2 SD of the triplicates was more than
0.2 were discarded.
Mutation detection
BRAF codon 600 and NRAS codon 61 were screened for
mutations on a LightCycler real-time PCR System
(Roche Diagnostics GmbH, Mannheim, Germany) by
melting curve analysis using fluorescent probes, as we
have previously described [11]. The accuracy of this
method was confirmed by direct sequencing of PCR
products that showed deviation from the WT genomic
DNA melting peak.
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Real-time quantitative PCR analysis
Real-time quantitative PCR was used to evaluate the
differential fold changes between the target and the
reference genes in 17 primary melanoma samples and to
confirm the aCGH results. The DNA copy-number alter-
ations of eight BAC clones localized on the 11q13.3
region (CTD-2192B11, CTB-36F16, RP1-88B16, RP1-
162F2, RP1-4E16, RP1-128I8, RP1-17L4, and CTC-
437H15; start bp: 69070147, end bp: 69960225) were
validated by quantifying the relative amounts of four tar-
get genes (CCND1, FGF3, FGF4, and FGF19), all located
in this particular chromosomal region, with real-time
quantitative PCR using two reference genes for normal-
ization, GNS (12q14.3) and UBE2E1 (3p24.2), as we pre-
viously described [11].
Fluorescence in situ hybridization
Dual-color fluorescence in situ hybridization (FISH)
probe (Vysis, Downers Grove, Illinois, USA) was used on
selected tumor samples to detect copy number alterations
on amplified and deleted regions, including DNA probes
specific for 9p21, 7q31, as described previously [16,17].
Data analysis
All BAC clones were mapped to the human genome
(February 2009) using data provided by the UCSC
genome browser site (http://genome.ucsc.edu/). From data
processing, all X-chromosome and Y-chromosome clones
were excluded. BAC clones, which are known to have
genomic variants according to the Database of Genomic
Variants (The Centre for Applied Genetics, Toronto, On-
tario, Canada, http://projects.tcag.ca/variation/), were omitted.
The log2-transformed data were subjected to copy-
number change analyses for the identification of regions
of amplification and deletion. To determine gains and
losses of each regions, the Analysis of Copy Errors
algorithm in CGH Explorer software 3.2 (Department
of Informatics, The Faculty of Mathematics and Natural
Sciences, Blindern, Oslo, Norway) was used with a false
discovery rate (FDR) of less than 0.01 [18]. Previously, 11
different algorithms were compared, which are most
frequently used for analyzing aCGH data [19]. In this
paper, they pointed out that some current implementa-
tions do not include any assessment of the statistical sig-
nificance of the reported copy number changes, although
quantitative statistics of the aberrations are critical to
decide which region to pursue for further analysis. Analy-
sis of Copy Errors is one of the two algorithms that
incorporates FDR so far. The CGH Explorer was also used
to obtain graphical illustrations of copy number alteration
frequencies in primary melanomas.
For the subsequent identification of high-level gains and
homozygous deletions in aCGH data, ratio thresholds
were used as described in previous studies [8]. These
were more than 0.55 (>B5 copies) and less than – 0.8,
respectively. Estimates of genome-wide aberration rates
were carried out by simply calculating the proportion of
BAC clones gained or lost in a specific tumor sample.
To identify BAC clones or regions that differ in copy
number between tumor subgroups, Fisher’s exact test
was applied. We used an FDR correction procedure to
adjust for multiple comparisons and denote these re-
sulting P values as adjusted P values [20]. To increase our
power for identifying regional changes in copy number
between tumor subgroups, we averaged log2 ratios over
windows of five consecutive BAC clones and used a two-
sample t-statistic to compare the average log2 ratio for the
tumor subgroups for each window. We calculated an
adjusted P value using a permutation-based procedure
of Westfall and Young [21].
Identification of the correlations between BAC clones or
regions in different tumor subgroups (BRAFmut, WT) was
achieved by calculating a standard Pearson’s correlation,
which defines the magnitude and direction of the linear
relationship between BAC clones to quantify whether
these are changing in a concordant, discordant, or un-
related manner. First, a subset of BAC clones was chosen
to distinguish the subgroups (see the following for
Table 1 Clinical and histopathological parameters of patients with
primary melanomas
Variables Number of primary melanomas
All tumors 47 (100%)
Tumor type
NM 19 (40.4%)
SSM 28 (59.6%)
Sex
Male 24 (51.1%)
Female 23 (49%)
Age (years)
20–50 15 (31.9%)
> 50 32 (68.1%)
Breslow thickness (mm)a
< 2.01 17 (36.2%)
2.01–4.00 9 (19.1%)
> 4.00 21 (44.7%)
Clark’s level
I, II, III 20 (42.6%)
IV, V 27 (57.4%)
Ulceration
Absent 19 (40.4%)
Present 28 (59.6%)
Metastasis formation
Nonmetastatic 20 (42.6%)
Metastatic 27 (57.4%)
Patient survival
Alive 29 (61.8%)
Exitus 18 (38.3%)
BRAFmut b
Absent 26 (57.8%)
Present 19 (40.4%)
NA 2 (4.3%)
NRASmut c
Absent 37 (84.1%)
Present 7 (15.9%)
NA 3 (6.4%)
NM, nodular melanoma; SSM, superficial spreading melanoma.
aThickness categories on the basis of the current melanoma staging system.
bThe distribution of the BRAF codon 600 mutation.
cThe distribution of the NRAS codon 61 mutation.
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specific criteria) and then a pairwise correlation was
computed for all of the BAC clones from the subset. BAC
clones were selected if either the difference in the BAC’s
gain or loss percentages between the tumor subgroups
(BRAFmut, NRASmut and WT) was more than 40% or if its
adjusted P value from the categorical or the windowed
analysis was less than 0.3 (similar to that applied by
Loo et al. [22]). We have chosen these selection criteria to
include BAC clones that may truly differ between tumor
subgroups but did not achieve statistical significance
because of insufficient power. It should be emphasized
that this procedure of selecting BAC clones does not bias
the correlation analysis because these selection criteria
were based on comparison between tumor subgroups,
whereas the correlations were calculated within each sub-
group. All the cited P values were adjusted for multiple
comparisons. The analyses were carried out in the open-
source statistical computing environment R (http://www.r-
project.org/).
Investigating the frequency of cross-talks changed in
primary melanomas
Cancers are often viewed as systems diseases [23]. In
cancer cells, large-scale modifications of signaling path-
ways, especially in cross-talks, are prevalent [24]. The
definition of cross-talk is as follows: if two proteins belong
to different pathways, then the signaling interaction be-
tween these two proteins is a cross-talk between their
pathways. To identify cross-talks, we used the SignaLink
database (http://signalink.org/), which provides a precise
mapping of signaling pathways and also inform if a sig-
naling protein belongs to more than one pathway [25]. To
assess gene alterations in eight gene signaling networks
[EGF/MAPK kinase (EGF), Insulin/IGF (IGF), TGF-b
(TGF), Wingless/WNT (WNT), Hedgehog (HH), JAK/
STAT (JAK), Notch (Notch), and Nuclear Hormone
Receptor (NHR)] we estimated the copy number changes
of each of these pathway genes using the closest BAC
clone within 2Mb. We considered a signaling interaction
to be altered if the copy-number change of at least one of
the participating genes was classified as a gain or a loss by
aCGH analysis, and then we simply calculated the average
frequency of altered cross-talks within and between dif-
ferent pathways for one particular tumor subgroup.
Random forest analysis
The random forest package [26,27] of the R-statistical
programming language (http://www.r-project.org/) was ap-
plied to calculate the random forest classification and
importance measures on the aCGH data related to the
EGF/MAPK pathway genes (clone number=138). The
feature importance score derived from the random forest
classifier was used to assess the association of a particular
set of genes with positive BRAF mutations. The para-
meters were set as follows: ntree=5000 (number of
trees) and mtry=11 (the number of randomly selected
variables per branching of the tree). The most important
15 genes were listed and sorted by their importance
measures (mean decrease Gini and mean decrease ac-
curacy) over 1000 simulation runs and an automatic rerun
was performed with a value of 3 for the mtry parameter
using only those 15 variables that were most important in
the original run. Cross-validation was performed; thus,
the model was developed on the training set (60%) and
validated on the test set (40%) of tumors.
Results
Mutation frequencies of BRAF and NRAS oncogenes in
primary melanomas
The mutation status for BRAF and NRAS oncogenes
(BRAFmut or BRAFWT, NRASmut or NRASWT) was suc-
cessfully defined for 44 tumors. Fifty-nine percent
(26/44) of primary melanomas had either BRAF or NRAS
mutations, but both mutations were never simultaneously
present in any of the samples analyzed. BRAF mutations
at codon 600 were found in 40% of lesions. NRAS
mutations at codon 61 were detected in only 16% of
tumors (Table 1). The BRAF mutation was significantly
associated with tumor thickness, being more frequent in
samples with more than 2mm Breslow thickness. The
NRAS mutation was significantly associated with metas-
tasis formation (primary data summarized in Table 2).
Genomic alterations in 47 primary cutaneous melanoma
cancer samples
We analyzed tumor DNA from 47 frozen tissue primary
melanoma samples. To identify the overall trends across
all of the tumors, we plotted the frequency of tumors
showing gain or loss for each BAC clones across the
genome (Fig. 1). We have listed the high frequency (>30%
of tumors) of regional gains (>5Mb) and losses in Table 3.
Correlation of copy number alterations with BRAF or
NRAS mutation status
To identify genomic alterations associated with BRAF or
NRAS mutational status, we compared three groups of
tumors: (a) BRAFmut primary melanoma (n=19); (b)
NRASmut primary melanoma (n=7); and (c) WT (wild-
type for both loci) primary melanoma (n=18).
First, we compared the gain and loss frequencies in
mutation groups (BRAFmut, NRASmut, WT). The average
frequency of copy number changes was higher in
BRAFmut tumors than in WT tissues (Mann–Whitney
test; P=0.04 and 0.01, for gains and losses, respectively).
Table 2 Associations of BRAF and NRAS mutations with patients’
clinicopathological parameters
Breslow thickness >2 mm P value
BRAFmut (n= 19) 17 0.009
BRAFWT (n= 26) 13
Metastasis formation
NRASmut (n= 7) 7 0.031
NRASWT (n= 37) 19
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However, no other differences were found in genome-
wide aberration rates between these groups.
The frequency patterns of copy number changes for each
group across the entire genome are shown in Fig. 2. We
used four different methods to identify BAC clones or
groups of BAC clones that showed more frequent loss or
gain in one tumor subgroup than another: (a) measure-
ments of difference in the frequency of gain or loss be-
tween subgroups were higher than 40%; (b) determina-
tion of significant differences in copy number changes in
individual BAC clones between subgroups using Fisher’s
exact test; (c) determination of statistical difference
between windows of five BAC clones with a two-sample
t-statistic; and (d) characterization of high-level loss and
gain in more than 20% of tumors in each subtype.
We have listed distinct chromosomal regions in Table 4,
which shows more frequent gains and losses (> 40%) in
one tumor subgroup than in another. Alterations exclu-
sively associated with BRAFmut were the gain of chro-
mosome 7 and 1q23–q25 and losses on the long arm of
chromosome 10. Losses of the 6q25.3–6q27, 11q23.3–
q25, and 17p13.3 loci were the most common DNA
alterations in NRASmut tumor samples. Loss of the 9p21.3
region and gain of 8q were more frequent in melanomas
with BRAFmut or NRASmut. Primary melanoma without
BRAF or NRAS mutations was primarily characterized by
alterations in chromosomes 17 and 4.
Using Fisher’s exact test to compare gain and loss of
individual BAC clones between BRAFmut and WT tumor
subgroups, we found that the loss of 45 clones from
the 10q23.3–10q26.3 region was mainly associated with
BRAFmut melanoma (adjusted P values<0.05). Using a
slightly less conservative level of significance (adjusted
P<0.1), we identified an additional 73 BAC clones at the
following locations: gains in 7p14.2–7q11.22 and 7q36.3
and losses in 1p33 and 10q21.1–10q23.31, which were
found to be more frequent in BRAFmut than in WT
tumors. Moreover, 29 BAC clones exhibited differences
between NRASmut and WT tumor subgroups (adjusted
Fig. 1
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Overall frequency of BAC copy number gain and loss for 47 primary melanomas. The percentage of the 47 tumors showing gain (red; above 0)
or loss (green; below 0) of DNA represented by each of the 2379 BAC is plotted against the corresponding genomic position of the BAC clone.
BAC, bacterial artificial chromosome.
Table 3 High frequency (>30%) of regional (> 5Mb) gains and
losses in 47 primary melanomas
Chromosome location Event Number of BAC clones
1p36.31–p36.21 Gain 7
1q21.1–1q25.3 Gain 24
1q31.3–1q32.1 Gain 11
6p25.3–6p12.3 Gain 43
7q31.2–7q31.33 Gain 11
8q11.21–8q12.3 Gain 20
8q21.11–8q24.3 Gain 57
11q13.1–11q13.4 Gain 29
15q22.2–15q25.1 Gain 20
17q25.1–17q25.3 Gain 17
19p13.3–19q13.42 Gain 36
20p11.21–20q13.2 Gain 44
22q11.21–22q13.32 Gain 16
1p36.22–1p35.2 Loss 15
2q22.1–2q32.2 Loss 49
4q13.3–q35.1 Loss 107
5q22.3–5q23.2 Loss 8
6q13–6q27 Loss 37
9p24.3–9q32 Loss 102
10p15.3–10q26.3 Loss 130
11q14.1–11q24.2 Loss 51
13q14.3–13q31.3 Loss 20
17p13.3–17q21.32 Loss 46
BAC, bacterial artificial chromosome.
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Fig. 2
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Frequency plots of copy number gain and loss in subgroups of primary melanomas. The percentages of copy number gain (red; above 0) and loss
(green; below 0) were calculated for (a) WT (n= 18), (b) BRAFmut (n= 19), and (c) NRASmut (n= 7) tumor tissues. *Regions significantly altered
(adjusted P value < 0.05) (or close to; adjusted P value < 0.1) between mutation subgroups. WT, wild-type.
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P value<0.1). Loss in 6q25.2–6q25.3 and 11q23.1–11q25
was mainly seen in tumors with NRASmut, but none of
these alterations were commonly seen in WT tumors.
Asterisks on Fig. 2 indicate the location of the BAC clones
showing differences between these primary melanoma
subgroups with this test. Our data show that the BAC
clones achieving a level of significance with Fisher’s exact
test are often part of a larger region that differs in the
frequency of gain or loss between these tumor subtypes.
To increase our power in identifying copy number gains
and losses larger than those identified by single BAC
clones, we applied a two-sample t-statistic comparing a
sliding window of five consecutive BAC clones in the
tumor subgroups. With this test, we observed differences
between NRASmut and WT tumor subgroups for BACs at
the following locations: 11q23.2, 11q24.1–11q24.2, and
11q25 (adjusted P values<0.1). There was also a sug-
gestive evidence of differences between BRAFmut and
WT tumor subgroups in 7q11.22, 7q11.23, 7q21.11,
10q11.23, 10q23.1, 10q23.1, 10q23.33–10q24.33, and
14q24.3 (adjusted P values<0.1).
To further characterize genomic differences between
tumor subgroups, we also compared the frequency with
which particular BAC clones showed high-level amplifica-
tions and homozygous deletions exceeding the upper or
lower thresholds (log2 ratioZ 0.55 or r – 0.8, respec-
tively). BAC clones showing such alterations in at least
20% of the tumors in a subgroup are listed in Table 5.
Frequent homozygous deletion was seen in both BRAFmut
and WT melanomas in the 17q21.32 region harboring the
HOXB3–9 gene cluster, which are members associated
with many malignant tumors [28]. Homozygous deletion
of the CDKN2A (9p21.3) gene was found only in 8.5% of
tumors (4/47).
Correlation of gain or loss changes in BRAFmut and
wild-type primary melanomas
Pairwise correlation analysis of the subset of BRAFmut and
WT tumors (including 519 and 167 BAC clones, res-
pectively; these clones exhibited more frequent loss or
gain in these tumor subgroups) revealed chromosomal
alterations that coexist more often together in these
groups of tumors. The heat maps of Fig. 3 show regions of
positive (change in same direction: green) and negative
(change in opposite direction: red) correlations between
certain regions. There were positive correlations (correla-
tion coefficient>0.7) between (a) loss in 1p34.2–1p32.2
and loss in 4q22.1–4q25; (b) loss in 1p13.2 and loss in
4q22.1–4q24; (c) loss in 1p21.3–p13.2 and loss in 14q23.2;
(d) loss in 4q35.1 and loss in 11q23.2–q23.3; and (e) gain
in 7q21.11–7q31.1 and gain in 20p12.2–20p12.1 in the
BRAFmut tumor group. Relatively large regions of negative
correlation (correlation coefficient<–0.7) were seen in
WT tumors between changes in the copy number of BAC
clones such as: (a) loss in 4q13.1–4q13.3 and gain in
14q24.1–14q32.2; (b) loss in 4q13.1–4q13.3 and gain
in 17q24.3–17q25.3; (c) loss in 4q23–4q25 and gain
in 14q24.1–14q32.2; (d) loss in 4q25 and gain in
17q24.3–17q25.3; (e) loss in 7q11.23–7q21.11 and gain
in 17p; (f) loss in 7q31.1–17q31.2 and gain in 17p; and
(g) loss in 7q31.31–7q31.32 and gain in 7p. Furthermore,
gain of several BAC clones from 14q24.1–14q32.2 showed
a positive correlation (correlation coefficient>0.7) with
copy number gain in the 17q25.1–q25.3 region in primary
melanomas without the BRAF or the NRAS mutation.
Identification of gene signature associated with the
BRAF mutation in the EGF/MAPK pathway
Because the BRAF oncogene is one of the key activators
of the EGF/MAPK pathway, we performed a focused
analysis of this signaling pathway to investigate whether
there are any gene signatures in this pathway that are
related to the BRAF mutation. We estimated the copy
number changes of each of these pathway genes using the
closest BAC clone within 2Mb. Using the random forest
Table 4 Chromosomal loci that showed more frequent (more than
40%) gain or loss in one tumor subtype than another (BRAFmut,
NRASmut, WT)
Chromosome location Event Number of BAC clonesa Association
BRAFmut vs. NRASmut
1q23.2–1q25.2 Gain 16 BRAFmut
7 chr Gain 191 BRAFmut
20q13.32 Gain 1 BRAFmut
1p34.2–1p33 Loss 3 BRAFmut
1p13.2 Loss 5 BRAFmut
4q13.3 Loss 3 BRAFmut
4q22.1–4q25 Loss 3 BRAFmut
10q21.3–10q22.1 Loss 2 BRAFmut
10q26.13–10q26.3 Loss 15 BRAFmut
6q25.3–6q27 Loss 4 NRASmut
11q23.3–11q25 Loss 21 NRASmut
17p13.3 Loss 2 NRASmut
BRAFmut vs. WT
1q24.1–q24.3 Gain 4 BRAFmut
1q25.3–1q31.2 Gain 4 BRAFmut
6p22.3 Gain 7 BRAFmut
7p22 Gain 11 BRAFmut
7p21.3–7p21.1 Gain 3 BRAFmut
7p15.3–7q36.3 Gain 128 BRAFmut
8q11.11–8q11.22 Gain 4 BRAFmut
8q24.11–8q24.3 Gain 31 BRAFmut
1p33–1p32.3 Loss 3 BRAFmut
9p21.1–9p13.3 Loss 6 BRAFmut
9p13.2 Loss 1 BRAFmut
10q11.21–10q26.3 Loss 93 BRAFmut
11q22.1 Loss 1 BRAFmut
11q23.1–11q23.2 Loss 6 BRAFmut
11q14.2–11q23.3 Loss 15 BRAFmut
NRASmut vs. WT
8q12.2–8q21.11 Gain 14 NRASmut
8q24.23–8q24.3 Gain 3 NRASmut
6q22.31 Loss 2 NRASmut
6q25.2–6q27 Loss 6 NRASmut
9p22.2–9p21.3 Loss 5 NRASmut
11q21–11q25 Loss 38 NRASmut
17p13.3–17p11.2 Loss 30 NRASmut
17q12–17q21.2 Loss 15 NRASmut
4q23–4q25 Loss 4 WT
17p11.2 Gain 4 WT
17q24.3–17q25.3 Gain 15 WT
BAC, bacterial artificial chromosome.
aNumber of BAC clones altered in the region.
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classifier among the EGF/MAPK pathway genes, we iden-
tified a signature of 15 genes that was highly predictive
for a BRAF-positive mutation status. A cross-validation
test was carried out for each set of genes to evaluate
the accuracy measures of the random forest model: the
overall accuracy was 87.5% (number of correct classifica-
tions), sensitivity was 77.8% (the proportion of true
positives), and specificity was 70% (the proportion of true
negatives). Frequent coamplification of well-known onco-
genes such as EGFR, PI3K, and several less known genes,
such as SHC1, PEA15, ELK4, was also found to be most
likely associated with the presence of the BRAF muta-
tion. We also observed a common deletion pattern in
three well-known tumor suppressor genes, PTEN, JNK1,
and HVH-3, which fell into these predictive sets of genes
and several less known genes, such as JNKK2, MEK2,
ATF2, TPBG, SOS1, SHOC2, and TGFBR1.
Frequent changes in signaling cross-talks in primary
melanomas harboring the BRAF mutation
We also aimed to investigate the frequency of copy number
changes of the signaling interactions between and within
eight tumor regulatory pathways in primary melanoma sub-
groups with different BRAF genotypes (BRAFmut: tumors
harboring the BRAF mutation; BRAFWT: tumors without
the BRAF mutation, which also includes tumors with the
NRAS mutation). The results of this analysis are shown
in Fig. 4. We observed that cross-talk between the EGFand
the JAK networks is extensively altered in the BRAFmut
tumors compared with the BRAFWT lesions. In addition,
interactions within the EGF–JAK, JAK–IGF, and EGF–IGF
pathways are more frequently altered (>20%). This anal-
ysis further supported the potentially important role of the
HH pathway in BRAFmut primary melanoma.
Validation of array comparative genomic hybridization
data by Q-PCR and fluorescence in situ hybridization
To validate some frequently found (>30% of primary
melanomas) regional gains in 11q13, 7q31, and losses in
9p21, we performed a detailed Reverse transcription poly-
merase chain reaction and FISH analysis. Real-time
quantitative PCR for four target genes located within
the 11q13.3 chromosomal segment was performed. A good
concordance was found between data derived from Q-
PCR and aCGH for 17 different samples. A mathematical
comparison was also conducted between the two ex-
perimental approaches. Spearman’s rank correlation was
carried out using the mean log2 values of each BAC clone
covering this particular region of interest, and the mean
log2 ratio of each target gene to reference genes was
revealed by Q-PCR. The correlation coefficient showed
strong correlations between the two results (Spearman’s
rank correlation r=0.7, P=0.003).
FISH was also applied for the following regions: 7q31,
9p21 for selected samples. Good agreement was found
between the two methods. An average of 5.8 copies
(range of 2.5–13.3) of 7q31 signals was found among the
10 cases that exhibited gain by aCGH analysis. All the
tumors that exhibited 7q31 gain by aCGH also showed
gain by FISH. Furthermore, an average of 1.6 copies
(range: 2.8–0.2) of 9p21 signals was detected among the
17 cases that exhibited loss by aCGH analysis. In four
samples, loss of the 9p21 region was detected by aCGH;
however, the average copy number of the 9p21 signal was
2.1, 2.1, 2.7, and 2.8 by FISH. The reason for this dis-
crepancy may be that the touch preparation and the DNA
were from slightly different parts of the tumor or a high
copy number heterogeneity existed within the sample.
Discussion
In this study, we used high-resolution array CGH to
evaluate the copy number changes in primary cutaneous
melanomas. aCGH identifies genomic imbalance at a
level of resolution higher than that achievable by classical
cytogenetic analysis. The higher resolution of genomic
screening has allowed a more detailed evaluation of the
DNA content. On the basis of the analysis of the 47
primary melanomas, we observed large regional gains in
1p36, 1q, 6p, 7q31, 8q, 11q13, 15q, 17q25, chromosome
20, 22q and losses in 2q, 4q, 5q22–q23, 6q, 9, chro-
mosome 10 and 17, 11q14–q24, and 13q, many of which
have been reported by previous studies using conven-
tional cytogenetic and CGH methods [29–31].
Through DNA copy-number profiling, we aimed to dis-
cern differentially altered chromosomal segments and
genes between BRAF and NRAS mutated melanoma sub-
groups. Somatic mutations of BRAF and NRAS oncogenes
are thought to be among the first steps in melanoma
initiation and it has been proved that they are preserved
throughout tumor progression. Therefore, drugs targeting
Table 5 The list of regions where the most common high-level
amplification and homozygous deletions were observed
Chromosome location Event Associationa
6p22.3 High-level amplification BRAFmut
7p21.3 High-level amplification BRAFmut
7p21.1 High-level amplification BRAFmut
7p15.3 High-level amplification BRAFmut
7p14.3 High-level amplification BRAFmut
7p14.1 High-level amplification BRAFmut
7p13 High-level amplification BRAFmut
7p12.3 High-level amplification BRAFmut
7p12.1 High-level amplification BRAFmut
7q31.2 High-level amplification BRAFmut
7q32.2 High-level amplification BRAFmut
7q35–q36.3 High-level amplification BRAFmut
8q24.13 High-level amplification BRAFmut
17q21.32 Homozygous deletion BRAFmut and WT
6p22.3 High-level amplification NRASmut
6p21.31 High-level amplification NRASmut
6p12.1 High-level amplification NRASmut
13q21.33–13q22.1 High-level amplification NRASmut
13q31.3–13q32.1 High-level amplification NRASmut
13q33.1 High-level amplification NRASmut
13q33.3 High-level amplification NRASmut
aIt was considered to be associated with a tumor subtype if at least 20% of
primary melanomas in that particular subgroup showed this genetic alteration.
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this pathway are the most attractive clinical agents for the
disease [32,33]. However, characterization of gene copy
number anomalies in primary melanomas in conjunction
with BRAF and NRAS mutational status can provide ratio-
nal additional targets for a combination therapy, which
may help to enhance the response and decrease the resis-
tance to BRAF and NRAS inhibitors.
Previous studies have revealed distinct genetic alterations
between melanoma subgroups on the basis of mutations
of the BRAF and NRAS genes [5,8–10]. Nevertheless, it
is important to emphasize that only two of these articles
provided data from primary melanomas. In agreement
with these earlier reports in primary melanomas with
BRAF mutations, we also found a higher frequency of
segmental chromosome 7 gain and chromosome 10 loss,
which always included BRAF on 7q34 and PTEN on
10q23.3, which were found to be less frequent in WT
tumors or in NRAS mutated lesions. In addition, the
group of tumors with BRAF or NRAS mutations also
frequently showed deletions in the 9p chromosomal
region, including the loci of CDKN2A (9p21.3). Further-
more, we also identified that loss of 11q23.3–11q25 was
more frequent in NRASmut compared with BRAFmut tumors.
In accordance with previous results, we also frequently
detected focal amplification in addition to the activating
mutations of the BRAF (7q34) gene. However, in contrast
to these previous findings, no correlation was found be-
tween the mutation status of the disease and chromosomal
loci harboring the TP53 (17p13.1) or CCND1 (11q13) gene,
but the loss of one allele at 17p13.3 distal to the TP53 gene
was observed frequently in NRASmut melanomas. This
second tumor suppressor locus on 17p has already been
observed in brain, breast, lung, and ovarian tumors [34–37];
two candidate tumor suppressor genes HIC1 and OVCA1
were identified at this locus [36,38,39]. It was also
suggested that the reduction to hemizygosity of 17p13.3
resulted in cell cycle deregulation and promoted tumor-
igenesis in ovarian cancer cells [39].
Using the frequency of high-level amplifications and
deletions and relatively conservative statistical methods
to highlight regions that differed significantly between
tumor subgroups, we found several regions of change
more frequently associated with BRAFmut or NRASmut
primary melanomas than lesions without BRAF or NRAS
mutations. Notably, several of the BAC clones that
showed greater frequency of loss or gain in one tumor
subgroup than another span large genomic regions whose
target genes are unknown. In BRAFmut melanomas, this
pattern is exemplified by the gains and losses involving
common tumor-associated regions at the 1q23–25, chro-
mosome 7 and 10q chromosome arm, respectively. This
observation is consistent with a previous model that sug-
gests a cooperative effect between the PTEN (10q23.31)
and BRAF (7q34) cancer genes in melanoma [40]. It has
been implied in several previous studies that the inacti-
vation of the PTEN tumor suppressor gene is a key
genetic event in melanoma [41]. In contrast, extended
deletions on chromosome 10 suggest a model wherein a
broad range of chromosome 10 losses in conjunction with
BRAF activation and PTEN inactivation may be involved
in polygenic melanoma tumorigenesis. Chromosome 10
deletions are highly prevalent even in early-stage primary
melanoma; however, the relative contribution of PTEN
inactivation in melanoma progression remains unclear
[42]. In addition, alterations mapped within the 11q23–
q25 locus that carries the well-established tumor
suppressor gene named OPCML were mainly associated
with NRASmut primary melanoma, indicating another pos-
sible link between loss in this region and the consecutive
activation of NRAS protein [43]. The observed distinct
genetic alterations that are related to the presence or the
absence of BRAF or NRAS mutations indicate that there
are alternative genetic pathways to melanoma.
The identification of high-level amplifications and homo-
zygous deletions in BRAFmut and NRASmut melanomas
revealed several regions on 7p, 7q, and 13q chromosome
arms that well differentiated these two genotypic sub-
types. Here, we highlight three specific regions, in which
alterations were frequently observed in other carcinomas
as well. The first is the 7q36.3 region harboring the
PTPRN2 gene that was found to be one of the most
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Differences in the frequency of altered cross-talks between BRAFmut
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The signal flow direction in the signaling interaction network is labeled
as ‘source’ or ‘destination’ on the figure (i.e. a protein from the source
pathway activates or inhibits a protein from the destination pathway).
Broad ranges of signaling interactions were more frequently altered
(> 20%) in BRAFmut melanoma compared with the BRAFWT tumor type
within the HH and between the EGF–JAK, IGF–JAK, and EGF–IGF
pathways.
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frequent high-level amplifications (14% of primary mela-
nomas) and was also linked to the presence of BRAFmut.
The product of this gene acts as a signaling molecule
involved in cell growth, differentiation, mitosis, and onco-
genic transformation. In a recent study, the downregula-
tion of a set of genes, including the PTPRN2, was able to
suppress metastasis of breast cancer cells to different
organ sites [44]. As the second example, high amplifica-
tion in 6p22.3 has been identified in both BRAF or NRAS
mutated melanomas altogether in 16% of the investigated
primary melanomas. The E2F3 candidate gene at this
region was already found to be overexpressed in several
bladder tumor cell lines with 6p22.3 amplification and
knockdown of E2F3 resulted in reduced proliferation of
cells [45]. E2F3 is a key repressor of the p19(Arf)-p53
pathway in normal cells [46]. The p19Arf-p53 tumor sup-
pressor pathway plays a critical role in cell-cycle check-
point control and apoptosis [47]. The third region involves
the 17q21.32 chromosome locus, which was found to be
the most frequent homozygous deletion in the investi-
gated primary melanomas (23% of primary melanomas),
whose prognostic importance has already been confirmed
in primary gastric cancers [48]. HOX genes at this region
are reported to be inappropriately expressed in the malig-
nant phenotype, suggesting an involvement of these regu-
latory proteins in oncogenic transformations [28].
It is well known that genetic events at different genomic
regions act concordantly in tumor development. There-
fore, we performed a correlation analysis between BAC
clones frequently altered in the investigated tumor sub-
groups to identify regions of chromosomal loss and gain
that commonly coexist in BRAFmut or WT primary mela-
nomas. It has to be mentioned that our analysis was
carried out on a relatively small set of tumors; thus, it only
begins to address the possible combinations of cooperat-
ing regions. The heat maps on Fig. 3 show trends of
correlation between chromosomal regions in the two
different melanoma subgroups.
Activation of the EGF/MAPK pathway by genetic
alterations is thought to be a main causative factor during
melanoma development, and their inhibition sensitizes
melanoma cells to certain anticancer agents [49]. Our aim
was to explore a relevant subset of gene copy number
alterations that have significant impacts on dysregulation
of the EGF/MAPK pathway along with the BRAF
mutation. A more complete understanding of the genetic
alterations that co-occur with mutations of BRAF could
help identify therapies that may act synergistically with
BRAF kinase inhibitors. The selection of relevant genes
for sample classification is one of the challenges in most
microarray studies where researchers try to identify the
smallest possible set of chromosomal loci or genes that
can still achieve good predictive performance. Random
forest analysis is increasingly being used in the field of
the evaluation of microarray experiments because it has
several characteristics that make it ideal to investigate
these datasets, such as (a) when the number of variables
is much larger than the number of observations and (b)
when datasets contain a large number of noisy vari-
ables [50–52]. With this method, a particular deletion
pattern involving three well-known cancer genes, such as
PTEN, HVH-3, and JNK1, was identified and found to be
associated with the BRAF mutation. PTEN is a well-
known tumor suppressor gene, but little data have been
published on the role of HVH-3 and JNK1 in melanoma
tumorigenesis. According to the literature, the expression
of HVH-3 resulted in both the specific inactivation and
the nuclear translocation of ERK2 [53], and it has been
proven that silencing the ERK2 mRNA inhibits tumor
growth in vivo [54]. There is also further evidence for the
role of the JNK1 gene in tumorigenesis: failure of the
function of JNK1 could facilitate tumor formation and
JNK1 – / – mice developed spontaneous intestinal tu-
mors [55,56]. We identified, moreover, a group of other
genes to be associated with the BRAF mutation, includ-
ing SHC1, PEA15, ELK4, EGFR, and PI3K, which have
evidence of oncogenic activity or may be potential
anticancer treatment targets [16,57]. We also observed
that their concomitant amplifications were highly pre-
dictive for the BRAF mutation. However, it is worth
mentioning that the BAC arrays have a relatively low
coverage; thus, we have estimated the copy number
changes of each of these pathway genes using the closest
BAC clone within 2Mb. Therefore, further experimental
follow-up at the expression and interactome level would
be needed to determine the exact role of these genes in
melanoma carcinogenesis.
Finally, investigating the frequency of the significantly
more frequently altered cross-talks among BRAFmut and
BRAFWT melanomas revealed the significant importance
of cross-talks between the EGF/MAPK–JAK, EGF/
MAPK–IGF, and JAK–IGF pathways and in the HH
pathway in BRAF mutated melanoma progression.
In conclusion, we found marked differences in the
genetic pattern of the BRAF or NRAS mutated and WT
melanoma subgroups. Therefore, our results also confirm
the involvement of distinct genetic pathways in melano-
ma tumorigenesis that are driven either through BRAF or
NRAS mutations. Nevertheless, these observations re-
quire further investigation with targeted higher resolu-
tion arrays along with studies of mRNA and protein
expression to confirm these relevant changes and to yield
more effective therapeutic approaches.
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